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Background. Many antimalarial interventions are accompanied by molecular monitoring of parasite infections,
and a number of molecular typing techniques based on different polymorphic marker genes are used. Here, we
describe a genotyping technique that provides a fast and precise approach to study Plasmodium vivax infection
dynamics during circumstances in which individual clones must be followed over time. The method was tested with
samples from an in vivo drug efficacy study.
Methods. The sizes of polymerase chain reaction fragments were evaluated by capillary electrophoresis to deter-
mine the extent of size polymorphism for 9 potential geneticmarkers (5 genes ofmerozoite surface proteins [msp] and
4 microsatellites) in 93–108 P. vivax–positive blood samples from 3 villages in Papua New Guinea.
Results. The microsatellites MS16 and Pv3.27 showed the greatest diversity in the study area, with 66 and 31
different alleles, respectively, followed by 2 fragments of msp1 and 2 other microsatellites. msp3, msp4, and msp5
revealed limited polymorphism.
Conclusions. Even for the most diverse markers, the highest allelic frequencies reached 6% (MS16) or 13%
(Pv3.27). To reduce the theoretical probability of superinfection with parasites that have the same haplotype as that
detected at baseline, we propose to combine at least 2 markers for genotyping individual P. vivax infections.
Plasmodium vivax is the second leading cause of human
malaria and, together with Plasmodium falciparum, ac-
counts for a huge majority of malaria cases worldwide.
Although P. falciparum is dominant in large parts of Af-
rica, P. vivax causes50% of all malaria cases outside of
Africa. In total, 2.5 billion inhabitants of the Middle
East, Asia, Eastern Africa, Central and South America,
and Oceania are exposed to P. vivax, resulting in an es-
timated 71–391 million cases of malaria per year [1–3].
In these areas, P. vivax is causing significant economic
and social damage [2], and there is increasing evidence
that severe illness and death due to P. vivaxmay bemore
common than previously appreciated [4–6]. Neverthe-
less, although considerable efforts were made during re-
cent decades to understand and control P. falciparum,
only limited resources have been invested in P. vivax
vaccine and drug research and development [7].
It has been argued that malaria control programs fo-
cusing predominantly on P. falciparum may foster P.
vivax endemicity [2, 8]. This effect might be caused by
different transmission strategies of the 2 parasites and
the ability of P. vivax to relapse from the hypnozoite
stage, a long-lasting liver stage that is activated through
unknown mechanisms [9]. Alternative approaches are
thus needed to effectively control P. vivax. Although the
development of a number of P. vivax vaccine candidates
is progressing [7], new combination drug regimens are
rarely rigorously tested for their efficacy against P. vivax.
This is partly because standard methods to differentiate
between true treatment failures and reinfections are
lacking. Because relapses are often genetically different
from infections present at the baseline of a drug trial [9],
distinguishing between recrudescence, new infection,
and relapse on the basis of genotyping results is further
complicated.
Similarly, despite recent efforts to fill gaps in knowl-
edge of the biology and epidemiology of P. vivax, little is
known about the basic parameters describing the course
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of natural infections, such as the duration or multiplicity of in-
fection (MOI) and the possible interaction with other Plasmo-
dium species. Intensified research of P. vivax will increase the
demand for genotyping tools, investigation of P. vivax infection
dynamics, and molecular monitoring during clinical trials.
Previously, P. vivax genotyping was usually performed by
polymerase chain reaction–restriction fragment length poly-
morphism (PCR-RFLP) analysis or by sequencing polymorphic
genes. Common markers were genes encoding merozoite sur-
face proteins (msp), the gene encoding circumsporozoite pro-
tein (csp), the gene encoding gametocyte antigen (gam-1), the
gene encoding Duffy binding protein (dbp), plus a number of
microsatellites. PCR-RFLP analysis revealed that the most poly-
morphic markers weremsp3, with 49 different alleles detected
in 94 isolates [10], and msp1, with 36 and 37 alleles detected in
100 and 151 isolates, respectively [11, 12]. Less polymorphic
were csp,with 23 alleles detected in 100 isolates [11], and gam-1,
with 5 alleles [13, 14]. Use of PCR-RFLP to study microsatellites
revealed up to 15 different alleles [15, 16]. Sequencing revealed
msp1 as highly polymorphic, with 31 alleles among 40 isolates
analyzed [17]. High diversity was also detected in msp3 [18],
msp5 [18, 19], and dpb [20–22].
Although PCR-RFLP is a cheap and reliable genotyping
method, it requires time-consuming analysis of restriction frag-
ments. Side-by-side runs on high-resolution gels are needed, es-
pecially when minor differences in fragment size occur. Multi-
clonal infections generate complex fragment patterns that are
difficult to analyze. Sequencing, on the other hand, usually has a
much higher resolution but is not suitable for multiple-clone
infections unless a preceding cloning step is included.
As an alternative to these 2 widely used methods, size poly-
morphism detection by capillary electrophoresis combined with
analysis software such as GeneMapper or GeneMarker has
proven to be a valuable tool for high-resolution genotyping of P.
falciparum [23]. Recently, this method was used to determine
the size of P. vivax microsatellites [9, 24–27]. Up to 43 alleles
were found at a single locus in samples from various regions
worldwide, indicating that this method is highly suitable for P.
vivax genotyping. The present study focuses on genetic diversity
at the community level, because this reflects the situation likely
encountered in drug surveillance or studies of infection dynam-
ics, and it evaluates the extent of size polymorphism for 9 poten-
tial genotyping markers by means of capillary electrophoresis in
93–108 blood samples from Papua New Guinea.
SUBJECTS, MATERIALS, AND METHODS
Study sites, subjects, and therapeutic classification. In vivo
drug-efficacy studies that accorded with the revised World Health
Organization (WHO) protocol were conducted between October
2004 and April 2005 in 3 villages in Papua New Guinea to assess
rates of amodiaquine failure and chloroquine plus sulfadoxine-
pyrimethamine failure in persons with uncomplicated P. falcipa-
rum and P. vivaxmalaria [28]. P. vivax from 108 community sam-
ples was genotyped (because of a shortage in material, 15 samples
could not be genotyped for microsatellites MS16 and Pv3.27). Of
108 cases of P. vivax infection in the in vivo studies, 13 involved
children who received a diagnosis of P. vivax infection during the
28-day in vivo efficacy trial. For these 13 patients, available samples
from days 7, 14, and 28 plus any day of treatment failure were ge-
notyped.
For patients in the in vivo drug efficacy study, treatment fail-
ure was defined as clinical deterioration in the presence of P.
vivaxparasitemia; as parasitemia onset 3–28 days after treatment
initiation and an axillary temperature of37.5°C; or as parasi-
temia onset 7–28 days after treatment initiation, irrespective of
clinical conditions [28]. For patients without clinical signs and
recurrent detection of asexual parasites 28 days after treat-
ment, the clinical and parasitological response to treatment was
considered adequate. Detailed information on treatment, pa-
tients, and outcome classificationwas published previously [28].
Protocol approval and ethical clearance for the study were
obtained from the Medical Research Advisory Committee
(MRAC 05.19) of the Ministry of Health in Papua New Guinea,
and consent was obtained fromparents or legal guardians before
recruitment of each patient. Blood samples, obtained via finger
prick, were collected into EDTA microtainer tubes, and DNA
was extracted using a QIAamp DNA blood kit (Qiagen) accord-
ing to the manufacturer’s instructions.
Genetic markers. Five of 9 markers tested are coding re-
gions ofmerozoite surface genes. Themsp1 gene contains a series
of conserved and variable stretches, which are described else-
where [17]; 2 regions, msp1F1 and msp1F3, proved to be the
most polymorphic in a previous study [11] and in our sequence
alignments of published sequences.msp3,msp4, andmsp5 each
contain a region in which the number of repeats varies among
parasites. The microsatellite markers Pv3.27, MS16, Pv1.501,
and Pv3.502 were selected because of the previously reported
extent of their polymorphisms [9, 24, 27].
PCR analysis. For amplification of all 9 genetic markers, a
nested or seminested approach was used. To size PCR products
by capillary electrophoresis, the forward primer of the nested
PCR was labeled with a fluorescent dye (NED, VIC, or 6-FAM
[Applied Biosystems]). Taq polymerase sometimes adds an ad-
enine at the 3' end of the PCR product. Because size variation
must be avoided, the reverse nested primer contained a propri-
etary 7-bp tail (Applied Biosystems) at its 5' end that promoted
the addition of an adenine at the 3' end of the labeled fragment.
The primer sequences are given in table 1. As negative controls,
pooledDNA fromhumanswithout infection and a P. falciparum
DNA sample were used.
PCR analyses were done in a total volume of 20 L that con-
tained 0.25 mol/L of each primer (obtained from Operon for
primary PCR and fromApplied Biosystems for nested PCR), 200
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mol/L of dNTPs, 2L of buffer B (Solis BioDyne), 2mmol/L of
MgCl2, 1.5U of TaqDNApolymerase (FirePol [Solis BioDyne]),
and 0.5 L of genomic DNA, corresponding to 0.5 L of blood.
One microliter of undiluted or diluted (at 1:100 or 1:1000) PCR
product was used as template for the nested or seminested PCR
(table 2).
PCR analyses were performed in an MJ Research PTC 100 or
a Biometra T Professional Basic thermocycler under the follow-
ing conditions: initial denaturation for 5 min at 95°C; 30 cycles
(primary PCRs) or 25 cycles (nested PCRs) of denaturation for 1
min at 95°C, annealing for 1 min at 55°C–62°C (table 2), and
elongation for 1 min at 72°C; and final elongation for 5 min at
72°C. PCR products were stored at 4°C in the dark until further
analyses.
Capillary electrophoresis and data analyses. PCR prod-
ucts were first analyzed on a 2% agarose gel. For capillary elec-
trophoresis, most nested PCR products were diluted to 1:20 in
H2O; a few samples were not diluted or were diluted to 1:40. A
total of 2.5 L of diluted PCR product was mixed with 10 L of
diluted size standard Rox-500 (Applied Biosystems; dilution
1:40 in H2O).
Themixwas dried overnight at room temperature in the dark;
capillary electrophoresis was done at the MRC genomics core
facility (London, United Kingdom), where 10 L of highly
deionized formamide (Applied Biosystems) was added to the
sample. The sample was then incubated at room temperature for
45 min and run on a 3730xls DNA analyzer (Applied Biosys-
tems).
Data were analyzed using GeneMarker, version 1.6 (Soft-
Genetics), to facilitate determination of fragment sizes and
peak intensity and to set cutoff values for distinguishing peaks
for existing fragments from background noise. All samples
were checked visually, and fragment sizes were remeasured at
a different dilution for peaks that were too high or too low.
Alleles were grouped manually according to their size into
3-bp bins for coding regions and according to their repeat
length for microsatellites (3 bp forMS16, 4 bp for Pv3.27, 7 bp
for Pv1.501, and 8 bp for Pv3.502).
Measures of diversity. In addition to the total number of
alleles distinguished, the distribution of allelic frequencies is an
important characteristic for determining the quality of genotyp-
ing markers. Low and evenly distributed frequencies and a large
number of alleles reduce the risk that a second infection involves
the same allele by chance. For each individual marker, the prob-
ability P of being infected by 2 parasites carrying the same allele
is equal to the expected homozygosity and was calculated using
the formula P p2i, where pi is the frequency of allele i [29].
To facilitate comparability with other published markers, the
expected virtual heterozygosityHE was also calculated, using the
equation [n/(n 1)]  (1  p2i), where n is the number of
samples analyzed. This variable can be defined as the probability
that a randomly chosen pair of alleles differ from each other.
The likelihood that 2 infections carry the same genotype by
chance is reduced by combining 1 unlinked genetic marker.
On the assumption that different infections are independent, the
probability of reinfection due to parasites with the same geno-
Table 1. Primer sequences for 9 genetic markers in Plasmo-
dium vivax.











































a Primer modified from Karunaweera et al. [25].
b Primer modified from Imwong et al. [27].
c Primers originally described by Imwong et al. [9].
d Primers originally described by Imwong et al. [11].
e Primers modified from Imwong et al. [11].
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type can be calculated by multiplying the probabilities of differ-
ent molecular markers.
Calculation of mean MOI. The MOI in 93–108 microscopy-
positive samples was calculated for all 9 markers independently by
dividing the total numberofP. vivax clones detectedby thenumber
of samples PCR positive for this parasite.
Classification of genotyping results. To discriminate re-
crudescence from new infection, genotypes at the time parasites
reappeared (defined as day X) were compared with genotypes in
the sample obtained before treatment (defined as day 0).
Follow-up samples were genotyped using msp1F1, msp1F3, the
microsatellites 1.501 and 3.502,msp3,msp4, andmsp5 asmark-
ers. According to the definition of new infection adopted by the
WHO andMMV [30], a new infection is a subsequent occurring
parasitemia in which all alleles in parasites from the posttreat-
ment sample are different from those in the admission sample,
for 1 or more loci tested. Any genotype detected in samples col-
lected on both days indicated recrudescence. In rare cases, par-
asites from a patient with relapsing infection that carried the
same genotype as parasites recovered onday 0might be classified
as recrudescence.
RESULTS
Diversity of 9 marker genes. To identify the most suitable P.
vivax genotypingmarker, we determined the prevalence of poly-
morphisms for 9 potential markers in 93–108 P. vivax–positive
blood samples from Papua New Guinea. Figure 1 shows the
numbers of alleles discriminated and the respective allelic fre-
quencies for all 9 markers.
For somemarkers, 1–8 of the 93–108 samples tested remained
PCR negative even after repeating the PCR under the same con-
ditions. This may be a result of sequence variation in the primer
binding sites or the detection limit of this particular PCR. A
summary of PCR results for different markers is given in table 3.
Allelic frequencies. Diversity was highest for the microsatel-
lites MS16 (P 0.023; HE  0.988) and Pv3.27 (P 0.07;
HE  0.94), followed bymsp1F3 (P  0.107;HE  0.902) and
msp1F1 (P 0.134; HE  0.875) (table 3). If MS16 and
Pv3.27—the most polymorphic microsatellites—were com-
bined, the probability that 2 samples would have the same geno-
type by chancewas reduced to 0.0016 for the combination. Table
4 lists the values of P for each marker and for combinations of
2–9 markers.
MOI. The mean MOI was highest (2.37) for microsatel-
lite MS16 and lowest (1.46) for msp5 (table 3 and table 5,
which appears only in the electronic edition of the Journal).
On the basis of 9 markers, 20 single-clone infections (MOI, 1)
were found among 108 samples, and the highest MOI de-
tected was 8.
msp1 F1 and F3 haplotypes in single infections. PCR
fragments were obtained for the msp1F1 and msp1F3 regions
in 18 of 20 single-clone infections. Because the F1 and F3 PCR
products detected in these samples originated from a single
msp1 gene, the number of differentmsp1 haplotypes could be
determined. In 18 samples, 8 msp1F1 alleles and 10 msp1F3
alleles were detected, leading to 17 distinct msp1 haplotypes.
All except 1 appeared only once, indicating that msp1 diver-
sity is by far greater than that indicated by 1 marker alone.
The long distance between the F1 and the F3 region (2800
bp in reference strain Salvador 1) did not allow spanning a
single PCR over both regions.
Distinguishing between treatment failures and new infec-
tions or relapses. P. vivax parasites in follow-up blood samples
from13 childrenwere genotyped. In 11 children (84.6%), parasites
were detected on day 28; clinical episodes occurred in 1 patient on
day 6 and in another on day 20. Infection in 4 of 13 patients was
classified as treatment failure (i.e., recrudescence). Among these
were the 2 children inwhomtreatment failurewas detected ondays
6 and 20. Nine children had a new infection or relapse.





















Microsatellite MS16 3 57 56 . . . 406 145–497 VIC
Microsatellite 3.27 4 58 58 . . . 301 184–325 6-FAM
Microsatellite 1.501 7 58 58 1:100 120 90–282 NED
msp1F3 3 59 60 . . . 260 226–372 VIC
msp1F1 3 55 55 . . . 400 344–533 NED
Microsatellite 3.502 8 58 58 . . . 168 131–231 6-FAM
msp3 3 60 60 . . . 463 312–481 VIC
msp4 3 58 58 1:100 245 167–265 6-FAM
msp5 3 60 62 1:1000 332 246–432 6-FAM
a In reference strain Sal-1, including a 7-bp tail and a terminal adenine.
Evaluation of P. vivax Genotyping Markers ● JID 2009:199 (1 April) ● 1077
DISCUSSION
Although P. vivax is the main causative agent of malaria outside
of Africa, remarkably little is known about the infection dynam-
ics of this pathogen under natural circumstances. A genotyping
system that can be used in large-scale studies is urgently needed
to strengthen the research on and control of P. vivax. Here, we
show results of an evaluation of differentmolecularmarkers and
demonstrate the usefulness of a precise and fast genotyping tech-
nique based on capillary electrophoresis for studies of P. vivax
populations. This technique detected extensive diversity for mi-
crosatellitesMS16 (16 alleles) and Pv3.27 (31 alleles); significant
diversity was also found in 2 other microsatellites (Pv1.501 and
Pv3.502), as well as in 2 regions of msp1. msp1 has been geno-
typed previously by use of PCR followed by separation on aga-
rose gels, leading to only 5msp1F1 and 4msp1F3 size variants in
Figure 1. Allelic frequencies of 9 potential genetic markers among 93–108 Plasmodium vivax–positive samples. n, number of alleles. aFrequency of
alleles without lettering is 1.5%.
Table 3. Diversity, PCR positivity, and multiplicity of infection (MOI) for 9 potential marker genes in Plasmo-
dium vivax.
MS16 Pv3.27 Pv1.501 msp1F3 msp1F1 Pv3.502 msp3 msp4 msp5
Alleles, no. 67 31 19 28 25 13 15 10 11
PCR positivitya 90/93 90/93 107/108 108/108 100/108 108/108 106/108 108/108 108/108
Clones, no. 213 166 204 232 189 178 183 163 158
MOI 2.367 1.844 1.907 2.148 1.890 1.648 1.726 1.509 1.463
P  pi2 0.023 0.070 0.099 0.106 0.134 0.145 0.202 0.273 0.288
HE 0.988 0.940 0.909 0.902 0.875 0.863 0.806 0.734 0.718
NOTE. MOI was calculated for each marker by dividing the number of clones detected in all positive samples by the number of
PCR-positive samples.
a Data are no. of samples with positive PCR results/no. of samples tested.
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100 samples and indicating a restricted resolution from this
technique. When RFLP analysis was applied to the F2 fragment
ofmsp1, 2 individual digests led to 36 different alleles [11]. PCR-
RFLP is labor-intensive, as it involves 2 digests per sample, and
difficulties arise in fragment sizing on gels, particularly in the
case of multiple-clone infections. The capillary electrophoresis
approach overcomes these limitations and is thus highly suitable
for large sample sets and for longitudinal tracking of individual
clones in cases such as drug trials.
Recently, different studies have used PCR followed by capillary
electrophoresis to evaluate a number of microsatellites, including
those used in this study. The extent of size polymorphism inmicro-
satelliteMS16was higher in our study than previously reported (66
alleles in 93 isolates, compared with 43 alleles in 164 isolates [24]).
The other microsatellites (i.e., 31 alleles at locus 3.27, 19 alleles at
locus 1.501, and 13 alleles at locus 3.502) showed polymorphisms
comparable to those reported fromMyanmar, Thailand, Laos, and
India,where80–92samplesweregenotypedpercountryand20–28
alleles at locus 3.27, 10–15 alleles at locus 1.501, and 7–14 alleles at
locus 3.502 were found [9, 27]. In contrast, these loci had shown
limited polymorphism in Colombia [27]. We determined an HE
valueof 0.94 for themarkerPv3.27 amongparasites recovered from
a limitedgeographic region inPapuaNewGuinea,which is remark-
ably similar to the value of 0.95 we calculated on the basis of data,
published elsewhere [27], for 90 P. vivax–infected blood samples
from India.
Comparison of the genetic diversity of potentialmarkers is com-
plicated because HE values for a single marker can greatly differ
between study sites [27]. It is difficult todeterminehowmuchof the
variation in discriminationpower depends on the genotyping tech-
nique and choice of marker and how much is due to underlying
differences in genetic diversity of the studypopulations. Theuseful-
ness of themarkers we tested for genotyping in PapuaNewGuinea
needs to be evaluated for each study site.
Some of our markers, such asmsp1, are negatively affected by a
high frequencyof themostcommonallele (29%for theF1 fragment
and 24% for the F3 fragment). Such a high allelic frequency in-
creases the risk that a relapse or new infection carries by chance a
genotype identical to the one detected at day 0. This unequal distri-
bution of frequenciesmight be explained by natural selection. Alle-
lic frequencies of microsatellites are generally more evenly distrib-
uted because of the absence of selective pressure.
The marker MS16 provided the highest MOI, with a mean of
2.4 P. vivax infections/carrier in our study, whereas in the same
population, the mean MOI for P. falciparum was 1.7 estimated
with the marker gene Pfmsp2 (J. Marfurt, unpublished data).
The higherMOI of P. vivax could reflect either greater complex-
ity due to relapses and different transmission intensities or
merely differences in the resolution of the 2 molecular markers
used. Longitudinal studies are required to further elucidate rates
of acquisition and elimination of P. vivax clones, compared with
those of P. falciparum.
Previously,P. vivax genotyping studies had been performed in
children from the same study area. The different results obtained
illustrate effects due to resolution of the typing technique used. A
meanMOI of 1.4 was detected bymsp3 PCR-RFLP [31], and a
mean MOI of 3.5 was found when cloned msp3 and Duffy
binding protein (dpbII) alleles were sequenced [32].
Our genotyping method was used for samples from a drug-
efficacy study. Among 13 patients who were P. vivax positive
after day 0, 4 treatment failures (i.e., persistent infections with
same genotype) and 9 new infections were found. Relapses in P.
vivax complicate the interpretation of genotyping in drug trials
as a novel genotype during the follow up period can either be
true new infection or a relapse. However, because a relapse in-
volving a different genotype would be considered a new infec-
tion and not a treatment failure, the discrimination “relapse/
new infection” is of little relevance to PCR adjustment of trials of
drugs against blood-stage parasites.
In principle, relapses can also lead to overestimation of recru-
descences if the relapse is of the same genotype as the infection at
baseline. AlthoughP. vivax strains in areas of endemicity, such as
New Guinea, are thought to have a short relapse interval [9, 33],
it is still unclear how frequent an infection present at baseline
and successfully treated relapses during the 28-day follow-up
period. However, other studies indicate that parasites involved
in relapse often carry a genotype different from those present at
baseline [9]. Therefore, it is unlikely that many relapses after a
baseline infection will falsely be considered as recrudescences.
Table 5. Multiplicity of infection (MOI) ob-
tained by different genotyping markers for Plas-
modium vivax.
The table is available in its entirety in the online
edition of The Journal of Infectious Diseases.
Table 4. Probability of the coincidence of the same genotype in
independent Plasmodium vivax clones.
Molecular
markera





MS16 0.023 P1  PMS16 0.02259252
Pv3.27 0.070 P2  P1  PPv3.27 0.00158892
Pv1.501 0.099 P3  P2  PPv1.501 0.00015794
msp1F3 0.107 P4  P3  Pmsp1F3 1.682  10	5
msp1F1 0.134 P5  P4  Pmsp1F1 2.2539  10	6
Pv3.502 0.145 P6  P5  PPv3.502 3.2592  10	7
msp3 0.202 P7  P6  Pmsp3 6.5673  10	8
msp4 0.273 P8  P7  Pmsp4 1.7902  10	8
msp5 0.288 P9  P8  Pmsp5 5.1613  10	9
a Ordered according to increasing values of P.
b The combined product Pi, calculated as P1  P2 . . .Pi, is the overall
probability that the genotype of 2 independent clones coincides both at the
locus corresponding to that line in the table and at all loci higher up in the table.
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Although no genotyping method can ultimately distinguish be-
tween relapses andnew infections or recrudescences, genotyping
improved the precision of trial findings considerably and thus
represents a clear improvement, comparedwith outcomes based
on microscopy findings only.
In conclusion, a high-throughput system based on PCR fol-
lowedby capillary electrophoresis is well suited for genotypingP.
vivax. For the PNG Institute of Medical Research in Papua New
Guinea, we recommend use of the marker MS16, eventually in
combination with microsatellite Pv3.27 or Pv1.501. As for frag-
ment sizing by capillary electrophoresis, a maximum of 3 differ-
ently labeled PCR products (plus a size standard) can be com-
bined [23], and no extra costs will occur when analyzing up to 3
markers. The probability that 2 independent infections carry the
same alleles was estimated to be 0.15% when MS16 and Pv3.27
were analyzed in combination. If an even higher resolution is
needed, the marker Pv.1.501 ormsp1F3 can be included, further
reducing the probability by a factor of almost 10 each. It remains
to be shownwhether thesemarkers are suitable for genotyping in
other geographic areas and, if so, which combinations are best.
This easy to use and fast genotyping system can provide the basis
for further investigations of the infection dynamics of P. vivax.
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Table 5. Multiplicity of infection (MOI) obtained by different genotyping markers for Plasmodium vivax.
MS16 3.27 1.501 msp1F3 msp1F1 3.502 msp3 msp4 msp5 Maximal MOI of all markers
PCR finding
ND ND 1 1 1 1 1 1 1 1
ND ND 1 1 1 1 1 2 1 1
1 1 1 1 1 1 1 1 1 1
ND ND 1 1 	 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 	 1 1 	 1 	 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
ND ND 1 1 1 1 	 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 	 1 1 1 1 1 1 1 1
ND ND 1 1 1 1 1 1 1 1
ND ND 1 1 1 1 1 1 1 1
ND ND 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
2 1 1 1 1 1 1 1 1 2
2 1 1 2 1 1 1 1 1 2
1 1 2 2 2 2 1 2 2 2
2 2 1 2 2 1 2 1 1 2
ND ND 2 1 	 1 1 2 1 2
2 1 2 1 1 1 1 2 2 2
1 1 2 2 2 1 2 1 1 2
ND ND 1 1 1 1 2 1 1 2
1 1 1 2 2 1 2 1 2 2
2 2 2 2 2 2 2 1 1 2
2 1 1 1 1 1 1 1 1 2
1 1 2 2 1 2 2 1 1 2
ND ND 2 2 2 1 1 2 1 2
2 1 1 2 	 1 1 1 1 2
2 1 1 1 1 1 1 1 1 2
2 2 1 2 1 2 1 2 1 2
1 1 1 2 1 1 2 1 1 2
2 1 1 2 1 1 1 1 1 2
1 1 1 1 2 1 1 1 1 2
1 2 1 1 2 2 2 2 1 2
1 2 1 1 1 1 1 1 1 2
2 2 2 2 2 2 2 1 2 2
2 1 1 1 1 1 1 2 1 2
3 2 2 2 1 2 2 1 1 3
ND ND 2 2 3 2 1 1 2 3
2 1 1 3 1 1 1 1 1 3
3 1 1 1 1 1 1 2 1 3
3 1 2 2 2 1 1 1 1 3
3 2 2 3 1 3 2 2 2 3
3 2 5 2 2 2 2 3 2 3
3 2 2 2 1 1 2 2 2 3
1 1 1 2 2 1 3 1 1 3
3 1 1 1 1 1 1 2 1 3
(continued)
Table 5. (Continued.)
MS16 3.27 1.501 msp1F3 msp1F1 3.502 msp3 msp4 msp5 Maximal MOI of all markers
2 3 1 3 3 2 2 1 1 3
1 1 	 3 1 1 1 1 1 3
3 1 1 1 	 1 1 1 1 3
1 2 2 3 3 1 1 3 2 3
3 3 2 3 3 2 2 2 2 3
2 2 2 3 3 3 3 2 3 3
3 	 1 1 1 1 1 1 1 3
1 1 1 2 3 1 2 1 2 3
ND ND 1 2 3 1 1 1 1 3
2 2 2 3 2 2 2 3 2 3
1 1 1 1 1 1 3 1 1 3
2 1 1 3 1 1 2 1 1 3
2 1 3 1 1 1 2 2 1 3
2 1 1 3 2 1 1 1 1 3
1 1 1 3 1 1 1 1 1 3
3 1 1 2 1 2 1 1 2 3
1 1 1 1 1 1 1 3 1 3
	 2 1 3 2 2 3 2 2 3
2 2 3 2 2 2 1 2 3 3
2 1 2 1 1 1 4 1 1 4
4 3 3 2 3 3 3 4 2 4
4 3 3 2 3 2 2 2 2 4
1 2 1 3 	 4 2 2 1 4
1 1 1 4 1 1 1 1 1 4
1 1 1 1 2 1 4 1 1 4
1 4 3 3 3 2 2 2 4 4
4 2 3 4 2 2 3 1 1 4
3 2 2 2 2 1 4 1 1 4
3 4 2 2 3 3 1 3 2 4
2 2 2 4 2 3 2 2 1 4
2 4 2 2 3 3 3 3 2 4
2 2 2 4 1 1 2 1 1 4
3 2 1 4 1 2 1 1 1 4
4 2 2 2 2 2 2 1 2 4
1 1 1 1 4 1 2 2 1 4
3 1 5 3 4 3 2 2 3 5
ND ND 5 4 5 3 5 4 4 5
3 1 5 1 1 1 1 1 1 5
5 4 5 3 4 3 2 3 2 5
5 1 1 1 	 2 1 1 1 5
ND ND 5 1 	 1 1 1 1 5
5 2 2 5 3 3 3 2 3 5
3 3 5 5 2 2 3 2 2 5
ND ND 1 1 5 1 2 1 1 5
4 4 3 5 1 4 2 2 2 5
5 5 4 1 3 2 2 1 1 5
5 1 2 5 3 4 1 2 3 5
	 5 5 6 4 4 3 1 4 6
5 1 6 4 1 3 3 1 1 6
6 3 5 4 3 4 3 3 3 6
3 5 2 3 6 2 2 2 1 6
	 4 7 5 3 3 3 4 3 7
7 2 4 4 4 4 2 1 4 7
8 4 1 5 3 1 3 3 2 8
7 8 4 6 4 5 4 1 2 8
(continued)
Table 5. (Continued.)
MS16 3.27 1.501 msp1F3 msp1F1 3.502 msp3 msp4 msp5 Maximal MOI of all markers
Total clones, no.
213 166 204 232 189 178 183 163 158 331
PCR-positive samples, no.
90 90 107 108 100 108 106 108 108 108
MOI
2.367 1.844 1.907 2.148 1.890 1.648 1.726 1.509 1.463 3.065
NOTE. ND, not done; 	, PCR negative.
